Compare Davita Inc (DVA) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Noble Corporation plc — how do they compare? Davita Inc trades at $230.93 (market cap $14.92B), while Noble Corporation plc trades at $40.32 (market cap $6.65B). The key difference: Davita Inc is far larger — about 2.2× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.8% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | NE | |
|---|---|---|
Market Cap | $14.92B | $6.65B |
Sector | Health | Technology |
52-Week High | $235.71 | $54.37 |
52-Week Low | $103.87 | $25.70 |
Enterprise Value | $27.47B | $7.90B |
Dividend Yield | — | 4.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Noble Corporation (NE) trades at $41.79, up 4.55% with a bullish technical signal supported by moving averages. The company maintains solid fundamentals with $3.29B revenue, 7.17% net margin, and positive cash flow of $228M in 2025. Recent contract wins in Brunei and the UK Continental Shelf worth over $136M demonstrate operational momentum ahead of Q2 2026 earnings on July 27.
Analyst consensus suggests moderate upside with a $50 price target, though mixed earnings history and elevated P/E of 29.15 warrant caution. Key risks include offshore drilling market volatility and execution on new contracts, while institutional sentiment remains divided with 31% buy ratings versus 25% sell recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
